Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Los Angeles, California Clear all
Completed Phase 2 Interventional

Therapies for Down Syndrome Regression Disorder

NCT05662228
View directory record Official record
Conditions
Down Syndrome, Regression
Interventions
Lorazepam, Intravenous immunoglobulin (IVIG), Tofacitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 30 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 24, 2026, 5:21 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Lutikizumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 24, 2026, 5:21 PM EDT
Completed No phase listed Observational

OCS Lung Expand Post-Approval Study - Expand Follow-Up Data Collection

NCT04194398
View directory record Official record
Conditions
OCS Lung System
Interventions
OCS Lung System
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Timeline
2018 – 2021
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Jul 24, 2026, 5:21 PM EDT
Recruiting No phase listed Observational

ASXL-Related Disorders Natural History Study

NCT03303716
View directory record Official record
Conditions
Bohring-Opitz Syndrome, ASXL1 Gene Mutation, Shashi-Pena Syndrome, ASXL2 Gene Mutation, Bainbridge-Ropers Syndrome, ASXL3 Gene Mutation
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 24, 2026, 5:21 PM EDT
Completed Phase 4 Interventional

A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

NCT00363116
View directory record Official record
Conditions
Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Interventions
Daclizumab
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
23
States / cities
Davis, California • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Jul 24, 2026, 5:21 PM EDT
Not listed Not applicable Interventional

Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers

NCT00446472
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Regranex®, Hydrogel
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Long Beach, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Jul 24, 2026, 5:21 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

NCT04624230
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Farmington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 24, 2026, 5:21 PM EDT
Completed No phase listed Observational

Approaches and Decisions for Acute Pediatric TBI Trial

NCT04077411
View directory record Official record
Conditions
Severe Traumatic Brain Injury
Interventions
Observational
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Jul 24, 2026, 5:21 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 24, 2026, 5:21 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

NCT00774930
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Lanreotide, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Los Angeles, California • Stanford, California • West Hollywood, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Jul 24, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional Results available

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

NCT03351244
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 409306, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
32
States / cities
Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jul 24, 2026, 5:21 PM EDT
Recruiting Not applicable Interventional

Automated Insulin for Management of Intrapartum Glycemia

NCT06883344
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Pregnancy, Pre-Gestational Diabetes
Interventions
Automated insulin delivery (AID) system, Intravenous (IV) insulin
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 24, 2026, 5:21 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Non-invasive Brain Mapping of Movement Facilitation in Parkinson's Disease

NCT05179187
View directory record Official record
Conditions
Parkinson Disease
Interventions
Movement task
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 24, 2026, 5:21 PM EDT
Completed Phase 2Phase 3 Interventional Results available

WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation

NCT00129545
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
WATCHMAN Left Atrial Appendage Closure Technology, Warfarin
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
58
States / cities
Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Jul 24, 2026, 5:21 PM EDT
Recruiting Not applicable Interventional

Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)

NCT07179601
View directory record Official record
Conditions
Internal Hemorrhoids, HAE
Interventions
Hemorrhoidal artery embolization
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 24, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

NCT01935934
View directory record Official record
Conditions
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Metastatic Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Uterine Corpus Carcinosarcoma
Interventions
Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • South Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 24, 2026, 5:21 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NCT02364557
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Spine, Prognostic Stage IV Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Interventions
Stereotactic Body Radiotherapy, Surgery
Radiation · Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
153
States / cities
Birmingham, Alabama • Goodyear, Arizona • Peoria, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 24, 2026, 5:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

NCT03847519
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
Interventions
ADXS-503, Pembrolizumab
Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 24, 2026, 5:21 PM EDT
Active, not recruiting No phase listed Observational

Multicenter ACL Revision Study (MARS)

NCT00625885
View directory record Official record
Conditions
Rupture of Anterior Cruciate Ligament
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
12 Years to 65 Years
Enrollment
1,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2029
U.S. locations
47
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Jul 24, 2026, 5:21 PM EDT
Not yet recruiting Phase 4 Interventional

Postoperative Steroid Use in Adolescent Idiopathic Scoliosis and Neuromuscular Scoliosis Patients

NCT06023043
View directory record Official record
Conditions
Neuromuscular Scoliosis, Adolescent Idiopathic Scoliosis
Interventions
Dexamethasone
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
9 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Jul 24, 2026, 5:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparing Two School-Based Sleep Health Interventions To Promote Sleep Quality in Youth

NCT07213908
View directory record Official record
Conditions
Sleep
Interventions
TS-C-STEP, Sleep Health Education (SHE)
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
12 Years to 18 Years
Enrollment
1,320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 24, 2026, 5:21 PM EDT
Recruiting No phase listed Observational

A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

NCT06504589
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 24, 2026, 5:21 PM EDT
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NCT04513717
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
594
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 24, 2026, 5:21 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

NCT05411094
View directory record Official record
Conditions
Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Olaparib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 24, 2026, 5:21 PM EDT